OPTISON

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug OPTISON contains one active pharmaceutical ingredient (API):

1	Perflutren UNII T8C6W1N6NW - HUMAN ALBUMIN MICROSPHERES
	When used in conjunction with diagnostic ultrasound, perflutren provides opacification of cardiac chambers, improvement in delineation of endocardial borders, enhancement of the Doppler signal, and visualisation of wall motion and blood flow within the heart.
	Read more about Perflutren

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OPTISON Dispersion for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V08DA01		V Various → V08 Contrast media → V08D Ultrasound contrast media → V08DA Ultrasound contrast media
Discover more medicines within V08DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1203051, 1203062
ES	Centro de información online de medicamentos de la AEMPS	98065002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	010529
FR	Base de données publique des médicaments	67461741
GB	Medicines & Healthcare Products Regulatory Agency	342677
IT	Agenzia del Farmaco	034650010, 034650022
LT	Valstybinė vaistų kontrolės tarnyba	1030336, 1030337
PL	Rejestru Produktów Leczniczych	100172034
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51612001, W51612002
US	FDA, National Drug Code	0407-2707
ZA	Health Products Regulatory Authority	34/28/0075